Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2016 16:07 ET | Source: Dermira, Inc.

Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update

- Topline results for the first of three Phase 3 trials for CIMZIA® reported - DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences - Acquired option to...
October 21, 2016 07:30 ET | Source: Dermira, Inc.

Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists

MENLO PARK, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
October 13, 2016 07:30 ET | Source: Dermira, Inc.

Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference

MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
October 03, 2016 02:00 ET | Source: Dermira, Inc.

CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

BRUSSELS, Belgium and MENLO PARK, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3,...
October 01, 2016 03:05 ET | Source: Dermira, Inc.

Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress

MENLO PARK, Calif., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
September 28, 2016 07:30 ET | Source: Dermira, Inc.

Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress

MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
September 20, 2016 16:05 ET | Source: Dermira, Inc.

Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan

Terms include $25 million upfront license payment to DermiraMaruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) --...
September 12, 2016 07:30 ET | Source: Dermira, Inc.

Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda

MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
August 08, 2016 16:12 ET | Source: Dermira, Inc.

Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Reported Topline Results for Two Late-Stage Clinical ProgramsRaised Approximately $136 Million in Net Proceeds from Follow-on Public OfferingUpdates Guidance for Topline Phase 3 CIMZIA®...
June 13, 2016 16:05 ET | Source: Dermira, Inc.

Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right